Artia Global Partners LP
CIK: 1937964
Last 13F
Aug 14, 2026
Next 13F
Nov 16, 2026 · in 7 days
Options Notional
$15.82M
Holdings (47)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 14, 2026
- ABVX
ABIVAX SA
$68.82M
516,447 sh13.08%-14.0% - INSM
INSMED INC
$62.8M
589,052 sh11.94%-6.3% - TRVI
TREVI THERAPEUTICS INC
$41.23M
2.21M sh7.84%+9.8% - BTSG
BRIGHTSPRING HEALTH SVCS INC
$36.08M
517,315 sh6.86%+861.5% - RVMD
REVOLUTION MEDICINES INC
$34.72M
185,390 sh6.60%+48.3% - ARGX
ARGENX SE
$27.59M
29,739 sh5.25%+0.0% - ALKS
ALKERMES PLC
$23.52M
448,964 sh4.47%New - TVTX
TRAVERE THERAPEUTICS INC
$19.26M
339,033 sh3.66%+379.5% - AZN
ASTRAZENECA PLC
$18.65M
98,376 sh3.55%+3.1% - NAMS
NEWAMSTERDAM PHARMA COMPANY
$17.08M
503,936 sh3.25%+0.0% - DNTH
DIANTHUS THERAPEUTICS INC
$15.89M
162,990 sh3.02%+0.0% - DGX
QUEST DIAGNOSTICS INC
$13.8M
65,122 sh2.62%+59.5% - IONS
IONIS PHARMACEUTICALS INC
$11.45M
144,376 sh2.18%+0.0% - EYPT
EYEPOINT INC
$10.97M
767,098 sh2.09%+0.0% - ALMS
ALUMIS INC
$7.84M
278,546 sh1.49%-14.3% - VKTX
VIKING THERAPEUTICS INC
$7.05M
180,731 sh1.34%+0.0% - CELC
CELCUITY INC
$6.21M
59,316 sh1.18%+280.8% - CYTK
CYTOKINETICS INC
$6.02M
70,700 sh1.14%+333.7% - MRK
MERCK & CO INC
$6M
46,700 sh1.14%+0.0% - RAPP
RAPPORT THERAPEUTICS INC
$5.77M
138,508 sh1.10%+0.0% - JNJ
JOHNSON & JOHNSON
$5.74M
22,600 sh1.09%+0.0% - GH
GUARDANT HEALTH INC
$5.72M
38,100 sh1.09%New - ABSI
ABSCI CORPORATION
$5.38M
464,444 sh1.02%New - SRRK
SCHOLAR ROCK HLDG CORP
$5.3M
96,285 sh1.01%+0.0% - SION
SIONNA THERAPEUTICS INC
$5.27M
119,741 sh1.00%+0.0% - ASND
ASCENDIS PHARMA A/S
$4.73M
17,740 sh0.90%+0.0% - ROIV
ROIVANT SCIENCES LTD
$4.59M
129,800 sh0.87%+0.0% - PALI
PALISADE BIO INC
$4.16M
1.99M sh0.79%+0.0% - EWTX
EDGEWISE THERAPEUTICS INC
$4.01M
98,800 sh0.76%+50.8% - BIIB
BIOGEN INC
$3.98M
18,437 sh0.76%+0.0% - XENE
XENON PHARMACEUTICALS INC
$3.92M
65,000 sh0.75%+0.0% - BLTE
BELITE BIO INC
$3.85M
24,989 sh0.73%+0.0% - MLYS
MINERALYS THERAPEUTICS INC
$3.72M
137,800 sh0.71%+0.0% - PROK
PROKIDNEY CORP
$3.69M
1.81M sh0.70%+0.0% - ELVN
ENLIVEN THERAPEUTICS INC
$3.66M
72,100 sh0.70%+245.0% - ORKA
ORUKA THERAPEUTICS INC
$3.18M
33,400 sh0.60%New - PTGX
PROTAGONIST THERAPEUTICS INC
$2.81M
22,951 sh0.53%+0.1% - UTHR
UNITED THERAPEUTICS CORP DEL
$2.71M
5,000 sh0.52%+0.0% - DRUG
BRIGHT MINDS BIOSCIENCES INC
$2.7M
38,407 sh0.51%+0.0% - KNSA
KINIKSA PHARMACEUTICALS INTL
$1.87M
29,200 sh0.35%+0.0% - CMPX
COMPASS THERAPEUTICS INC
$839K
383,200 sh0.16%New - PRAX
PRAXIS PRECISION MEDICINES I
$837K
2,500 sh0.16%+0.0% - KOD
KODIAK SCIENCES INC
$663K
17,019 sh0.13%+0.0% - TENX
TENAX THERAPEUTICS INC
$612K
42,080 sh0.12%+0.0% - NUVL
NUVALENT INC
$605K
4,900 sh0.12%+0.0% - PEPG
PEPGEN INC
$370K
205,324 sh0.07%+0.0% - SYRE
SPYRE THERAPEUTICS INC
$355K
4,000 sh0.07%New
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 ABVX ABIVAX SA | 516,447 | $68.82M | -14.0% | 13.08% | Q2 2026 |
 INSM INSMED INC | 589,052 | $62.8M | -6.3% | 11.94% | Q2 2026 |
 TRVI TREVI THERAPEUTICS INC | 2.21M | $41.23M | +9.8% | 7.84% | Q2 2026 |
 BTSG BRIGHTSPRING HEALTH SVCS INC | 517,315 | $36.08M | +861.5% | 6.86% | Q2 2026 |
 RVMD REVOLUTION MEDICINES INC | 185,390 | $34.72M | +48.3% | 6.60% | Q2 2026 |
 ARGX ARGENX SE | 29,739 | $27.59M | +0.0% | 5.25% | Q2 2026 |
 ALKS ALKERMES PLC | 448,964 | $23.52M | New | 4.47% | Q2 2026 |
 TVTX TRAVERE THERAPEUTICS INC | 339,033 | $19.26M | +379.5% | 3.66% | Q2 2026 |
 AZN ASTRAZENECA PLC | 98,376 | $18.65M | +3.1% | 3.55% | Q2 2026 |
 NAMS NEWAMSTERDAM PHARMA COMPANY | 503,936 | $17.08M | +0.0% | 3.25% | Q2 2026 |
 DNTH DIANTHUS THERAPEUTICS INC | 162,990 | $15.89M | +0.0% | 3.02% | Q2 2026 |
 DGX QUEST DIAGNOSTICS INC | 65,122 | $13.8M | +59.5% | 2.62% | Q2 2026 |
 IONS IONIS PHARMACEUTICALS INC | 144,376 | $11.45M | +0.0% | 2.18% | Q2 2026 |
 EYPT EYEPOINT INC | 767,098 | $10.97M | +0.0% | 2.09% | Q2 2026 |
 ALMS ALUMIS INC | 278,546 | $7.84M | -14.3% | 1.49% | Q2 2026 |
 VKTX VIKING THERAPEUTICS INC | 180,731 | $7.05M | +0.0% | 1.34% | Q2 2026 |
 CELC CELCUITY INC | 59,316 | $6.21M | +280.8% | 1.18% | Q2 2026 |
 CYTK CYTOKINETICS INC | 70,700 | $6.02M | +333.7% | 1.14% | Q2 2026 |
 MRK MERCK & CO INC | 46,700 | $6M | +0.0% | 1.14% | Q2 2026 |
 RAPP RAPPORT THERAPEUTICS INC | 138,508 | $5.77M | +0.0% | 1.10% | Q2 2026 |
 JNJ JOHNSON & JOHNSON | 22,600 | $5.74M | +0.0% | 1.09% | Q2 2026 |
 GH GUARDANT HEALTH INC | 38,100 | $5.72M | New | 1.09% | Q2 2026 |
 ABSI ABSCI CORPORATION | 464,444 | $5.38M | New | 1.02% | Q2 2026 |
 SRRK SCHOLAR ROCK HLDG CORP | 96,285 | $5.3M | +0.0% | 1.01% | Q2 2026 |
 SION SIONNA THERAPEUTICS INC | 119,741 | $5.27M | +0.0% | 1.00% | Q2 2026 |
 ASND ASCENDIS PHARMA A/S | 17,740 | $4.73M | +0.0% | 0.90% | Q2 2026 |
 ROIV ROIVANT SCIENCES LTD | 129,800 | $4.59M | +0.0% | 0.87% | Q2 2026 |
 PALI PALISADE BIO INC | 1.99M | $4.16M | +0.0% | 0.79% | Q2 2026 |
 EWTX EDGEWISE THERAPEUTICS INC | 98,800 | $4.01M | +50.8% | 0.76% | Q2 2026 |
 BIIB BIOGEN INC | 18,437 | $3.98M | +0.0% | 0.76% | Q2 2026 |
 XENE XENON PHARMACEUTICALS INC | 65,000 | $3.92M | +0.0% | 0.75% | Q2 2026 |
 BLTE BELITE BIO INC | 24,989 | $3.85M | +0.0% | 0.73% | Q2 2026 |
 MLYS MINERALYS THERAPEUTICS INC | 137,800 | $3.72M | +0.0% | 0.71% | Q2 2026 |
 PROK PROKIDNEY CORP | 1.81M | $3.69M | +0.0% | 0.70% | Q2 2026 |
 ELVN ENLIVEN THERAPEUTICS INC | 72,100 | $3.66M | +245.0% | 0.70% | Q2 2026 |
 ORKA ORUKA THERAPEUTICS INC | 33,400 | $3.18M | New | 0.60% | Q2 2026 |
 PTGX PROTAGONIST THERAPEUTICS INC | 22,951 | $2.81M | +0.1% | 0.53% | Q2 2026 |
 UTHR UNITED THERAPEUTICS CORP DEL | 5,000 | $2.71M | +0.0% | 0.52% | Q2 2026 |
 DRUG BRIGHT MINDS BIOSCIENCES INC | 38,407 | $2.7M | +0.0% | 0.51% | Q2 2026 |
 KNSA KINIKSA PHARMACEUTICALS INTL | 29,200 | $1.87M | +0.0% | 0.35% | Q2 2026 |
 CMPX COMPASS THERAPEUTICS INC | 383,200 | $839K | New | 0.16% | Q2 2026 |
 PRAX PRAXIS PRECISION MEDICINES I | 2,500 | $837K | +0.0% | 0.16% | Q2 2026 |
 KOD KODIAK SCIENCES INC | 17,019 | $663K | +0.0% | 0.13% | Q2 2026 |
 TENX TENAX THERAPEUTICS INC | 42,080 | $612K | +0.0% | 0.12% | Q2 2026 |
 NUVL NUVALENT INC | 4,900 | $605K | +0.0% | 0.12% | Q2 2026 |
 PEPG PEPGEN INC | 205,324 | $370K | +0.0% | 0.07% | Q2 2026 |
 SYRE SPYRE THERAPEUTICS INC | 4,000 | $355K | New | 0.07% | Q2 2026 |
1-47 of 47 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Artia Global Partners LP
Artia Global Partners LP is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1937964). Signal8 holds 20 13F filings from it. Its SEC filings list Delaware as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 14, 2026. That report lists 47 securities, not counting options, down from 48 in Q1 2026.
Its five largest reported positions, in order, are ABIVAX SA (ABVX), INSMED INC (INSM), TREVI THERAPEUTICS INC (TRVI), BRIGHTSPRING HEALTH SVCS INC (BTSG) and REVOLUTION MEDICINES INC (RVMD). The next five are ARGENX SE (ARGX), ALKERMES PLC (ALKS), TRAVERE THERAPEUTICS INC (TVTX), ASTRAZENECA PLC (AZN) and NEWAMSTERDAM PHARMA COMPANY (NAMS).
Recent 13F filings by Artia Global Partners LP
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 47 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 48 securities.
- Q4 2025: 13F-HR filed Feb 17, 2026, listing 50 securities.
- Q3 2025: 13F-HR/A filed Nov 14, 2025, listing 48 securities.
- Q3 2025: 13F-HR filed Nov 14, 2025, listing 48 securities.
- Q2 2025: 13F-HR filed Aug 14, 2025, listing 33 securities.